Public Health Nutrition Program, Department of Epidemiology, New York University School of Global Public Health, New York, NY, United States.
Institute for Implementation Science and Health, Kathmandu, Nepal.
JMIR Res Protoc. 2024 Oct 21;13:e59423. doi: 10.2196/59423.
The prevalence of gestational diabetes mellitus (GDM) is increasing, particularly in low- and middle-income countries (LMICs) like Nepal. GDM self-management, including intensive dietary and lifestyle modifications and blood glucose monitoring, is critical to maintain glycemic control and prevent adverse outcomes. However, in resource-limited settings, several barriers hinder optimal self-management. Mobile health (mHealth) technology holds promise as a strategy to augment GDM treatment by promoting healthy behaviors and supporting self-management, but this approach has not yet been tested in any LMIC.
This report describes the protocol to develop a culturally tailored mHealth app that supports self-management and treatment of GDM (GDM-Dhulikhel Hospital [GDM-DH] app, phase 1) and test its usability and preliminary efficacy (phase 2) among patients with GDM in a periurban hospital setting in Nepal.
The study will be conducted at Dhulikhel Hospital in Dhulikhel, Nepal. In the development phase (phase 1), a prototype of the GDM-DH app will be developed based on expert reviews and a user-centered design approach. To understand facilitators and barriers to GDM self-management and to gather feedback on the prototype, focus groups and in-depth interviews will be conducted with patients with GDM (n=12), health care providers (n=5), and family members (n=3), with plans to recruit further if saturation is not achieved. Feedback will be used to build a minimum viable product, which will undergo user testing with 18 patients with GDM using a think-aloud protocol. The final GDM-DH app will be developed based on user feedback and following an iterative product design and user testing process. In the randomized controlled trial phase (phase 2), newly diagnosed patients with GDM (n=120) will be recruited and randomized to either standard care alone or standard care plus the GDM-DH app from 24-30 weeks gestation until delivery. In this proof-of-concept trial, feasibility outcomes will be app usage, self-monitoring adherence, and app usability and acceptability. Exploratory treatment outcomes will be maternal glycemic control at 6 weeks post partum, birth weight, and rates of labor induction and cesarean delivery. Qualitative data obtained from phase 1 will be analyzed using thematic analysis. In phase 2, independent 2-tailed t tests or chi-square analyses will examine differences in outcomes between the 2 treatment conditions.
As of July 2024, we have completed phase 1. Phase 2 is underway. The first participant was enrolled in October 2021, with 99 participants enrolled as of July 2024. We anticipate completing recruitment by December 2024 and disseminating findings by December 2025.
App-based lifestyle interventions for GDM management are not common in LMICs, where GDM prevalence is rapidly increasing. This proof-of-concept trial will provide valuable insights into the potential of leveraging mHealth app-based platforms for GDM self-management in LMICs.
ClinicalTrials.gov NCT04198857; https://clinicaltrials.gov/study/NCT04198857.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/59423.
妊娠糖尿病(GDM)的患病率正在上升,特别是在尼泊尔等中低收入国家(LMICs)。GDM 的自我管理,包括强化饮食和生活方式的改变以及血糖监测,对于维持血糖控制和预防不良结局至关重要。然而,在资源有限的环境下,有几个障碍阻碍了最佳的自我管理。移动医疗(mHealth)技术有望通过促进健康行为和支持自我管理来增强 GDM 的治疗效果,但这种方法尚未在任何 LMIC 中进行测试。
本报告描述了开发一种文化适应性的 mHealth 应用程序以支持 GDM 自我管理和治疗(GDM-Dhulikhel 医院[GDM-DH]应用程序,第 1 阶段)的方案,并在尼泊尔的一家城郊医院环境中测试其在 GDM 患者中的可用性和初步疗效(第 2 阶段)。
研究将在尼泊尔的 Dhulikhel 医院进行。在开发阶段(第 1 阶段),将根据专家审查和以用户为中心的设计方法开发 GDM-DH 应用程序的原型。为了了解 GDM 自我管理的促进因素和障碍,并收集对原型的反馈,将对 12 名 GDM 患者(n=12)、5 名医疗保健提供者(n=5)和 3 名家庭成员(n=3)进行焦点小组和深入访谈,如果没有达到饱和,则计划进一步招募。反馈将用于构建最小可行产品,该产品将通过使用出声思维协议对 18 名 GDM 患者进行用户测试。最终的 GDM-DH 应用程序将根据用户反馈以及迭代产品设计和用户测试过程进行开发。在随机对照试验阶段(第 2 阶段),将招募新诊断为 GDM 的患者(n=120),并从 24-30 孕周至分娩随机分配至标准护理组或标准护理加 GDM-DH 应用程序组。在这项概念验证试验中,可行性结果将是应用程序使用情况、自我监测依从性以及应用程序的可用性和可接受性。探索性治疗结果将是产后 6 周的产妇血糖控制、出生体重以及引产和剖宫产的发生率。从第 1 阶段获得的定性数据将使用主题分析进行分析。在第 2 阶段,将使用独立的双侧 t 检验或卡方分析检验两种治疗条件之间的结果差异。
截至 2024 年 7 月,我们已经完成了第 1 阶段。第 2 阶段正在进行中。第一名参与者于 2021 年 10 月入组,截至 2024 年 7 月,已有 99 名参与者入组。我们预计将于 2024 年 12 月完成招募,并于 2025 年 12 月发布研究结果。
在 GDM 患病率迅速上升的中低收入国家,基于应用程序的生活方式干预措施在 GDM 管理中并不常见。这项概念验证试验将为利用基于 mHealth 应用程序的平台在 LMICs 中进行 GDM 自我管理提供有价值的见解。
ClinicalTrials.gov NCT04198857;https://clinicaltrials.gov/study/NCT04198857。
国际注册报告标识符(IRRID):DERR1-10.2196/59423。